February was a packed month for interesting molecules – there were nearly 20 molecules we thought about including in this list but couldn’t fit them all. There are several clinical candidates this month including mobocertinib, an exon 20 mutant inhibitor that was recently given Breakthrough Therapy Designation by the FDA. Also included are several interesting modes of action here including two degraders, multiple protein dimerizers, and a mechanism-based inhibitor that modifies its target’s substrate. Finally, chemists will appreciate some interesting structures on this list as well as the femtomolar inhibitor CPI-1328 with a reversible potency among the strongest ever recorded.